Clinical trials: Viral Shedding
Influenza Virus
Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults
Influenza virus infections are a major cause of morbidity and mortality. The limited existing knowledge about the impact of influenza in immunocompromised patients suggests that they are at increased risk of influenza virus…
- Trial name
- NCT00998803
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- St. Jude Children's Research Hospital
Influenza, Pneumonia
Oseltamivir Randomised Controlled Efficacy Trial
Background In preparation for a global influenza pandemic, there is an urgent need for representative data from populations and settings where the pandemic is most likely to arise.
- Conditions
- Influenza, Pneumonia, Lower Respiratory Tract Infection, Upper Respiratory Tract Infection
- Trial name
- NCT00707941
- Testing
- Oseltamivir
- Where
- Bangladesh
- Volunteers
- 1,190 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Rotavirus Diarrhea, Vaccine Virus Shedding
Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh
Oral polio and rotavirus vaccines are significantly less effective in children living in the developing world. Tropical enteropathy, which is associated with intestinal inflammation, decreased absorption and increased…
- Conditions
- Rotavirus Diarrhea, Vaccine Virus Shedding, Tropical Enteropathy
- Trial name
- PROVIDE (NCT01375647)
- Testing
- IPV (inactivated polio vaccine), Rotarix
- Where
- Bangladesh
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Keratoconjunctivitis Due to Adenovirus, Viral Shedding
A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis
The investigators are conducting this study because the patient have an eye infection which is called adenoviral conjunctivitis, and is the most common cause of "pink eye". There is currently no treatment for this condition.
- Trial name
- NCT01533480
- Testing
- Zirgan, genteal gel
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Lifelong Vision Foundation
Covid19
Viral Shedding, Symptoms and Exposure of SARS-CoV-2 in Non-hospitalized Children With COVID-19
Data on COVID-19 in children are still scarce, and their role in SARS-CoV-2 transmission is poorly described. Furthermore, documentation of the best SARS-CoV-2 sampling methods in children are limited.
- Trial name
- NCT04666207
- Testing
- PCR
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Influenza
Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)
The primary objective of this study was to determine the proportion of subjects, seronegative to all three strains of influenza, as defined by a serum hemagglutination inhibition antibodies (HAI) antibody titer of <1:10, who shed…
- Trial name
- NCT00192387
- Testing
- CAIV-T, Liquid
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain
This randomized, double-blind, multi-center study of Tamiflu (Oseltamivir) will evaluate the efficacy against viral activity, the effectiveness in resolving the disease symptoms, and the safety and tolerability in patients with…
- Trial name
- NCT01032837
- Testing
- Oseltamivir
- Where
- 100 sites in United States
- Volunteers
- 102 people
- Sponsor
- Hoffmann-La Roche
Healthy
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children
The primary objective of this study is to describe the 28-day post-final dose safety and tolerability of three doses of MEDI-559 at 10^5 FFU when administered to healthy RSV seronegative children 1 to <24 months of age.
- Trial name
- MEDI-559 (NCT00767416)
- Testing
- MEDI-559
- Where
- 76 sites in United States, Puerto Rico
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Novel (H1N1) Influenza
Virus Shedding and Environmental Deposition of a Novel Influenza Virus
An influenza pandemic has recently been declared, involving the novel A(H1N1) 'swine flu' virus. This has spread to almost 100 countries worldwide in less than two months, causing widespread disease so far in Mexico, USA and…
- Trial name
- NCT01046734
- Where
- 3 sites in United Kingdom
- Volunteers
- 105 people
- Sponsor
- University of Nottingham
Upper Respiratory Tract Infections, Virus
Edinburgh and Lothian Virus Intervention Study in Kids
ELVIS Kids is a parallel, open label, randomised controlled trial (RCT) of Hypertonic Saline (HS) nose drops (~2.6% NaCl) vs. standard care in children <7 years of age with symptoms of an Upper Respiratory Tract Infection (URTI).
- Conditions
- Upper Respiratory Tract Infections, Virus, Virus Shedding, Pediatric ALL
- Trial name
- ELVIS Kids (NCT03463694)
- Testing
- Na Cl solution
- Where
- United Kingdom
- Volunteers
- 407 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Influenza
A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and Flumist
The purpose of this research is to compare the safety and ability to stimulate antibodies (part of the bodies proteins that fight infections) of two influenza (flu) vaccines given to children 12 to 35 months old.
- Trial name
- NCT00231907
- Testing
- FluMist, Fluzone
- Where
- 3 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants
Primary objective of this study is to describe the safety and tolerability of multiple doses of MEDI-534 in children 6 to less than (<) 24 months of age and in infants 2 months of age.
- Trial name
- NCT00686075
- Testing
- MEDI-534, Cohort 1, MEDI-534, Cohort 2, MEDI-534, Cohort 3
- Where
- 100 sites in United States, Australia and 7 more
- Volunteers
- 1,338 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC